PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
Bristol-Myers Squibb

Bristol Myers Squibb/Pfizer: patient organisation YouTube video sponsorship not clearly declared from the outset

Anonymous complaint upheld: sponsorship of a patient organisation’s YouTube video was not clearly apparent at the outset. Panel found breaches of Clauses…

2020
CASE
AUTH/3408/10/20 Amgen ⭐ Case of the Week

AUTH/3408/10/20: Anonymous non-contactable v Amgen (Blincyto) – No breach (prescribing information alleged out of date)

Anonymous complaint alleged Blincyto detail aid prescribing information was incorrect/out of date. Panel found complainant provided no supporting detail and ruled no…

2019
CASE
AUTH/3281/11/19 Sanofi

Sanofi breached Clause 9.1 over use of 0845 number for medical information line (AUTH/3281/11/19)

Public complaint about Sanofi’s medical information responses. Most allegations not proven, but use of an 0845 number (without clear cost info) was…

2020
CASE
AUTH/3420/11/20 Takeda

Takeda voluntary admission: uncertified UK HCP webinar invitation and missing prescribing information (AUTH/3420/11/20)

Takeda’s regional office (Switzerland) mistakenly emailed UK HCPs an uncertified invite linking to a registration page referencing Alofisel without prescribing information. Breaches…

2021
CASE
AUTH/3522/6/21 GlaxoSmithKline

AUTH/3522/6/21: Health professional v GlaxoSmithKline (Trelegy Ellipta) – No breach

A health professional challenged Trelegy Ellipta COPD ads (BTS meeting supplement and gskpro webinar page) as implying use in all COPD patients…

2021
CASE
AUTH/3463/1/21 Lundbeck

AUTH/3463/1/21: Lundbeck corporate website – recertification lapse upheld (Clause 14.5), other website/pipeline allegations not proven

Complaint about Lundbeck UK corporate website pages and links to global content. Panel found a breach for failing to recertify material within…

2021
CASE
AUTH/3476/2/21 Leo Pharma ⭐ Case of the Week

AUTH/3476/2/21: Anonymous (contactable) v Leo Pharma – LinkedIn profile allegations (No breach after appeal)

Complaint alleged a Leo employee’s LinkedIn CV-style β€œExperience” section promoted medicines and used β€œsafe” improperly. Panel found some breaches, but the Appeal…

2021
CASE
AUTH/3506/4/21 Daiichi-Sankyo UK

Daiichi-Sankyo: Lixiana journal ad breached overleaf prescribing information signposting rules (AUTH/3506/4/21)

A Lixiana print journal ad was cleared on imagery and dosing allegations, but breached the Code for failing to signpost that prescribing…

2021
CASE
AUTH/3490/3/21 Britannia Pharmaceuticals

Britannia Pharmaceuticals: failure to disclose investigator-led trials and poor documentation (AUTH/3490/3/21)

Britannia admitted it hadn’t disclosed certain investigator-led trials. The Panel couldn’t rule on trial disclosure clauses due to missing information, but found…

2021
CASE
AUTH/3510/5/21 Lundbeck

Lundbeck Migraine Preceptorship: alleged pre-licence promotion of eptinezumab (Vypeti) at internal training – No breach (AUTH/3510/5/21)

Complaint alleged pre-licence promotion of eptinezumab and inappropriate β€œexciting/innovative” wording at a Lundbeck-funded migraine preceptorship. Panel found no evidence of promotion or…

2021
CASE
AUTH/3552/8/21 Roche Products

Roche Resources website: mobile view hid prescribing information and AE reporting statements (AUTH/3552/8/21)

Roche’s HCP website displayed required prescribing information and adverse event reporting statements less prominently on some smartphones (moved into a hamburger menu…

2021
CASE
AUTH/3577/11/21 Ross ⭐ Case of the Week

Thornton & Ross webinar invite: sponsorship not clear at the outset (AUTH/3577/11/21)

A webinar invitation email appeared to come from an independent organisation and did not mention Thornton & Ross. Sponsorship was only disclosed…

2021
CASE
AUTH/3579/11/21 Novartis Pharmaceuticals UK

Novartis employees’ LinkedIn β€˜likes’ and comment on Glivec/Gleevec ruled misleading and public promotion (AUTH/3579/11/21)

Two Novartis employees β€˜liked’ and one commented on a patient advocate’s LinkedIn post about Gleevec/Glivec. The Panel found misleading, unsubstantiated claims and…

2022
CASE
AUTH/3611/2/22 Daiichi-Sankyo UK

Daiichi Sankyo: NICE TA694 summary card for Nilemdo/Nustendi failed to make simvastatin >40mg contraindication immediately apparent (AUTH/3611/2/22)

A NICE TA694 summary card referenced use with statins but didn’t make the simvastatin >40mg contraindication immediately apparent in the main body.…

2022
CASE
AUTH/3625/3/22 Allergan

Allergan: JuvΓ©derm UK website links alleged to promote Botox via US sites and social media (AUTH/3625/3/22) – No breach

Complaint alleged JuvΓ©derm UK site linked users to US Botox promotional pages/social media. Panel found matter in scope but ruled no breach…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training